Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05859659

Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)

Primary central nervous system (CNS) tumors, the vast majority (>90%) occurring in the brain and the remainder occurring in the meninges, spinal cord, and cranial nerves, showing an annual incidence of about 6-8 people per 100,000 population but its effects on health-care systems is out of proportion with incidence due to the substantial high rates of morbidity and mortality. Among which, glioma disease is the most common primary malignant CNS tumor, while the glioblastoma that showed the highest degree of malignancy and the worst prognosis accounts for 70-75%.

The construction goal of this project is to construct a multivariate retrospective CNS tumor database (over 50,000 cases, including 10,000 glioma) integrating clinical information, preoperative magnetic resonance imaging examination and molecular pathological results, and a prospective glioma database (3,000 cases) integrating advanced magnetic resonance sequences and postoperative follow-up. It aims to form a standardized database integrating magnetic resonance imaging, pathological results, and clinical-prognostic information.

Based on the construction of the above standardized database, the specifications for the acquisition of cranial magnetic resonance images, the image segmentation, tumor classification and labeling process, and the expert consensus on database construction and use management of CNS tumors were established. We aim to form a multimodal, large-capacity, high-quality, and rich medical imaging database that conforms to the characteristics of Chinese groups and clinical diagnosis and treatment norms. On this basis, the data are dynamically updated, in-depth mining, and the classification and grading standards of CNS tumor diseases, prognosis judgment criteria and treatment efficacy evaluation system are formulated, and providing comprehensive resources of retrospective data and prospective cohorts for large-scale reasearches, such as classification or treatment intervention predictions.

Recruiting

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • (1) a clear diagnosis of glioma based on pathological results;
  • (2) The MRI sequence is complete and there are no obvious artifacts in the image;
  • (3) The patient signs an informed consent form

Exclusion criteria

  • (1) Suffering from other neurological diseases;
  • (2) Prior to enrollment, surgery or biopsy, or a history of radiation therapy or chemotherapy;
  • (3) Unable to complete clinical scoring and related laboratory tests, unable to complete follow-up;
  • (4) Unable to tolerate MRI examination; Poor image quality, such as motion artifacts.

Treatment and study plan

This study does not intervene in this process.

Diagnostic Test

This study does not intervene in this process.

Primary outcomes

  1. Establish standardized clinical-MRI-molecular markers database for CNS tumors

    Time frame: 2022.06-2023.12

    Collecting at least 50,000 retrospective data of CNS tumors patients, including preoperative brain MRI, clinical infromations, histopathology resuluts, and molecular markers, to establish a multi-modal clinical-MRI-molecular database

  2. Establish prospective brain tumor cohort with multiomics information

    Time frame: 2022.06.01-2030.12.31

    Prospectively include at leaset 10,000 patients with brain space occupying lesions comfirmed by neuroimaging, recording their pre- and postoperative brain MRI, imaging diagnosis, histopathology or molecular pathology results, clinical intervention, treatment effect, and survival time.

Secondary outcomes

  1. Accurately predicting the molecular and survival of glioma patients based on a deep learning model

    Time frame: 2022.01-2024.12

    Build a MRI-based deep-learning model to predict molecular and survival on glioma.

Other outcomes

  1. Establish a large-scale foundation model for brain tumors on MRI

    Time frame: 2024.12-2026.12

    Developing artificial intelligence (AI) tools for brain tumors diagnosis and prediction using the retrospective MRI database with paired imaging reports and histopathological labeling, and conducting internal tests on the prospective cohort to evaluate AI model performance.

Study contacts

Contact information is provided by the study sponsor or research team.

Junjie Li, Master

CONTACT

[email protected]

86-19834515120

Yaou Liu, Doctor

CONTACT

[email protected]

+86 1059975396

Sponsors and collaborators

Lead sponsor

Yaou Liu

Other

Registry information

Important dates

Study start
2022
Primary completion
2030
Study completion
2030
First posted
May 16, 2023
Registry last updated
Mar 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.